Home > Insider Trading > Filing (0000920465-20-000123)

Filing Details

Accession Number:: 0000920465-20-000123
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-07-29 17:24:15
Reporting Period:: 2020-07-28

Accepted Time:: 2020-07-29 17:24:15
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1373707	Tetraphase Pharmaceuticals Inc	TTPH	Biological Products, (No Disgnostic Substances) (2836)	CA

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
920465	La Jolla Pharmaceutical Co	4550 Towne Centre Court San Diego CA 92121		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, Par Value $0.001 Per Share	Acquisiton	2020-07-28	3,737,360	$2.00	4,822,360	No	4	P	Indirect	See Explanation of Responses

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Explanation of Responses

Footnotes

This Statement of Changes in Beneficial Ownership on Form 4 is being filed by La Jolla Pharmaceutical Company, a California corporation ("Parent"). The securities described herein were acquired pursuant to a tender offer (the "Offer") by TTP Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser") to purchase all of the outstanding shares of common stock, par value $0.001 per share (the "Shares"), of Tetraphase Pharmaceuticals, Inc., a Delaware corporation, at a price of $2.00 per Share plus one non-transferable contractual contingent value right per Share on the terms and subject to the conditions set forth in the Offer to Purchase, dated June 29, 2020 (as amended by the Schedule TO-T/A filed by Parent and Purchaser with the U.S. Securities and Exchange Commission ("SEC") on July 29, 2020).
Following the reported transaction: (a) Purchaser beneficially owns directly the 3,737,360 Shares it purchased in the Offer; and (b) Parent beneficially owns indirectly an aggregate of 4,822,360 Shares, comprised of: (i) the 3,737,360 Shares that Purchaser purchased in the Offer; and (ii) the 1,085,000 Shares that Parent acquired through a series of open-market purchases made between June 10, 2020 and June 19, 2020 (as reported on a Statement of Beneficial Ownership on Schedule 13D filed with the SEC on June 22, 2020) and contributed to its non-wholly owned subsidiary, La Jolla Pharmaceutical Holdings, LLC, a Delaware limited liability company ("Holdings") on July 23, 2020. Parent is the Manager of Holdings and has the sole power to exercise voting and investment control over the Shares held by Holdings. Parent holds direct equity interests in each of Purchaser and Holdings.